Exelixis Inc - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi EXEL

Exelixis, Inc. (EXEL) operates on a high-scalability model where colossal development costs are followed by low-cost drug production. The absolute operating profit figures provided by GURU.Markets demonstrate financial stability, while the 1038.78 indicator reflects current dynamics. The company is implementing AI and robotics to accelerate drug design, yet reliance on Cabometyx sales and patents creates significant risks.

Exelixis Corp - Bathi operasional EBITDA EXEL (periode 23.11.2025 - 10.11.2026)

Exelixis (EXEL) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Rega bursa Exelixis Inc.|EXEL - Target konsensus

- rincian nilai pasar emiten:

Nilai pasar Exelixis|EXEL - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- informasi kapitalisasi buku:

Rega Buku Saham Exelixis|EXEL - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku exelixis.com|EXEL - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi Exelixis, Inc.|EXEL - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas Exelixis Inc|EXEL - Gunggung utang perusahaan|Utang-utang marang nilai buku Exelixis|EXEL - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Exelixis|Likuiditas darurat exelixis.com

- rincian asil keuangan lan kelipatan valuasi:

EXEL - Bathi resik|Prakiraan bathi resik Exelixis, Inc.|EXEL - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi exelixis.com|EXEL - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Exelixis|EXEL - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Exelixis|EXEL - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan exelixis.com|EXEL - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Exelixis, Inc.

Ringkesan analitik perusahaan:Exelixis, Inc.

To find a fundamental floor, it is critical for an investor to assess the business's real liquidity. Michael Morrissey has effectively transformed Exelixis, Inc. (EXEL) into a profitable mechanism by monetizing oncology drugs. This EBITDA chart measures the daily cash flow from core operations. The metric excludes non-cash expenses, exposing true operational efficiency. The stability of this indicator confirms the asset's high reliability.

Analisis pesaing Exelixis, Inc.